Quick Answer
Zomedica Corp. reported Cash and Equivalents of $9.02 million for fiscal year 2025.
Zomedica Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $9.02M | +28.4% |
| 2024 | $7.02M | -45.8% |
| 2023 | $12.95M | -52.7% |
| 2022 | $27.40M | -85.9% |
| 2021 | $194.95M | +214.5% |
| 2020 | $61.99M | +12041.3% |
| 2019 | $510.6K | -73.7% |
| 2018 | $1.94M | -43.7% |
| 2017 | $3.45M | +6.9% |
| 2016 | $3.23M | -0.5% |
| 2015 | $3.24M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.50M | -23.1% | -7.8% |
| June 30, 2025 | $8.13M | +2.4% | -8.0% |
| March 31, 2025 | $8.84M | -19.2% | +25.9% |
| December 31, 2024 | $7.02M | -45.8% | -28.0% |
| September 30, 2024 | $9.75M | -55.3% | +22.8% |
| June 30, 2024 | $7.94M | -71.6% | -27.4% |
| March 31, 2024 | $10.94M | +31.0% | -15.5% |
| December 31, 2023 | $12.95M | -52.7% | -40.5% |
- Zomedica Corp. showed an increase of +28.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2015–2025 period, Zomedica Corp.’s cash and equivalents has grown by 178.0% (from $3.24 million to $9.02 million).
- The most recent figure is from Zomedica Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: